$ whoami

WHAT THIS SITE IS

onlinesermorelin is an independent editorial project that publishes summaries of the peer-reviewed and regulatory research literature on sermorelin (GHRH 1-29 NH2). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is organized as a Unix manpage. Each major page maps to a manpage section — NAME, SYNOPSIS, DESCRIPTION, MECHANISM, PHARMACOKINETICS, HISTORY, SEE ALSO, BUGS, REFERENCES. The structure is the point: the published record on sermorelin is unusually well-documented (two FDA NDAs, a preserved Federal Register finding, a thirty-year clinical dataset, a precise pharmacokinetic profile, a clean WADA listing) and reads cleanly as a reference document rather than a sales page.

WHAT 'ONLINE' MEANS HERE

The 'online' modifier in onlinesermorelin.com is editorial framing — a position the publisher occupies relative to the literature. It signals an online-research-reading-room: the published record on sermorelin, brought into one searchable, structured, citation-anchored place that a researcher, science writer, anti-doping analyst, or curious reader can read without arriving on a wellness clinic landing page.

It is not a claim that this site offers consultations, prescriptions, telehealth, dispensing, or any healthcare service. The 'online' modifier does not change that. We do not see patients, we do not write prescriptions, and we do not refer to clinics or compounding pharmacies.

EDITORIAL STANDARDS

Every quantitative claim on every page cites a real study from the published peer-reviewed literature or a regulatory primary document. The references page lists all 19 sources with DOIs and direct PubMed, PMC, FDA Federal Register, or WADA URLs.

We do not invent research. We do not extrapolate beyond what the cited trial actually showed. Where evidence is class-level (for example the tesamorelin cognitive trial as a GHRH-class signal), we mark it as class-level rather than as a sermorelin finding.

We do not name compounding pharmacies, telehealth providers, research-chemical vendors, or product brands. Trademarks of the original FDA-approved sermorelin product, its former sponsor, and recombinant human growth hormone brands are deliberately avoided — they are not necessary to summarize the published record, and naming them would shift the editorial register from documentary to commercial.

We do not recommend doses. The dosage page documents what was studied — by whom, at what dose, in what population, by what route, for how long — with citations. It is a structured summary of the published record, not a protocol.

WHAT THIS SITE IS NOT

Not a clinic. Not a pharmacy. Not a telehealth provider. Not a supplier of sermorelin or any other peptide. Not affiliated with any compounding pharmacy or 503B outsourcing facility. Not affiliated with the former sponsor of the original FDA-approved sermorelin product or with any GH-related product manufacturer.

Not medical advice. The site reports what the research literature and regulatory record say about sermorelin. Decisions about diagnosis, treatment, or use of any compound are between a person and their qualified healthcare provider — not us.

CORRECTIONS

Errors and source corrections are welcome. The contact page describes how to submit a correction. If a cited source is misrepresented, a regulatory status has changed, or a newer trial supersedes a finding we summarize, we want to know.